Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL -0.83%56 Debt-to-EBITDA is 1.98 as of Dec. 2025, which is 25% above its 10-year median of 1.59. GuruFocus rates ASX:ACL with a GF Score™ of 56/100 and a GF Value™ of A$3.06 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 114 Medical Diagnostics & Research companies, Australian Clinical Labs ranks better than 58.77% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Australian Clinical Labs's Debt-to-EBITDA or its related term are showing as below:
ASX:ACL'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.72 Med: 1.59 Max: 1.82
Current: 1.75
During the past 6 years, the highest Debt-to-EBITDA Ratio of Australian Clinical Labs was 1.82. The lowest was 0.72. And the median was 1.59.
ASX:ACL's Debt-to-EBITDA is ranked better than 58.77% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.32
vs ASX:ACL: 1.75
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Australian Clinical Labs Debt-to-EBITDA Related Terms
Australian Clinical Labs Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:ACL vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Australian Clinical Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Australian Clinical Labs (ASX:ACL) has a Debt-to-EBITDA of 1.98 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Australian Clinical Labs. This is 25% above median its historical median of 1.59. Over the past decade, Australian Clinical Labs' Debt-to-EBITDA has ranged from 0.72 to 1.82. According to the industry distribution chart, Australian Clinical Labs ranks #47 out of 114 companies in the Medical Diagnostics & Research industry, placing it in the top 41.2%.
Is Australian Clinical Labs' Debt-to-EBITDA too high?
Australian Clinical Labs' current Debt-to-EBITDA of 1.98 is 25% above median its 10-year median of 1.59. Over the past 10 years, this metric has ranged from a low of 0.72 to a high of 1.82. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.32. Australian Clinical Labs' value of 1.98 is 14.7% below this industry median. Based on the distribution chart, Australian Clinical Labs ranks #47 out of 114 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Australian Clinical Labs has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #47 out of 114 companies for Debt-to-EBITDA. This puts Australian Clinical Labs in the upper half of its industry. The industry median Debt-to-EBITDA is 2.32. Australian Clinical Labs' value of 1.98 is 14.7% below this benchmark. Historically, Australian Clinical Labs' own Debt-to-EBITDA has ranged from 0.72 to 1.82 over the past decade. While the company's 10-year median is 1.59 vs. the industry median of 2.32, Australian Clinical Labs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.32, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Australian Clinical Labs's current Debt-to-EBITDA of 1.98 is 14.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Australian Clinical Labs. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Australian Clinical Labs's current Debt-to-EBITDA is 1.98, which is 25% above median its own 10-year median of 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Modestly Undervalued. The stock's GF Value™ is A$3.06, compared to a current price of A$2.38 — trading 22.2% below its estimated fair value. The current Debt-to-EBITDA is 1.98, which is 25% above median its 10-year median of 1.59 and 14.7% below the Medical Diagnostics & Research industry median of 2.32. Australian Clinical Labs' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current Debt-to-EBITDA is 1.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.38 is trading 22.2% below its estimated GF Value™ of A$3.06.
GuruFocus considers Australian Clinical Labs to be Modestly Undervalued.
Key valuation signals for ASX:ACL:
Debt-to-EBITDA: 1.98 (25% above median its 10-year median of 1.59)
GF Value™: A$3.06 vs. price of A$2.38 (22.2% below fair value)
Industry Position: 14.7% below the Medical Diagnostics & Research median (#47 of 114)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
56GF Score
Get the complete analysis for ASX:ACL
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
